Complete spontaneous regression of giant focal nodular hyperplasia of the liver: Magnetic resonance imaging evaluation with hepatobiliary contrast media

Giuseppe Mamone, Settimo Caruso, Kelvin Cortis, Roberto Miraglia

Giuseppe Mamone, Settimo Caruso, Roberto Miraglia, Department of Diagnostic and Therapeutic Services, IRCCS ISMETT (Mediterranean Institute for Transplantation and Advanced Specialized Therapies), 90127 Palermo, Italy
Kelvin Cortis, Medical Imaging Department, Mater Dei Hospital, MSD2090 Msida, Malta

Author contributions: Mamone G designed this paper with input from Miraglia R; Caruso S wrote this paper with Mamone G and selected the pictures; Cortis K reviewed the first draft of the article and the bibliography; Miraglia R critically reviewed the article and approved the final version to be submitted; Miraglia R takes responsibility for the integrity and the accuracy of the data.

Institutional review board statement: The Institutional Research Review Board reviewed and approved this case report, with waiver of the informed consent.

Informed consent statement: A written informed consent to the MR procedures was obtained after a full explanation of the purpose and nature of the procedure.

Conflict-of-interest statement: We declare no conflict of interest.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Manuscript source: Unsolicited manuscript

Correspondence to: Giuseppe Mamone, MD, Department of Diagnostic and Therapeutic Services, IRCCS ISMETT (Mediterranean Institute for Transplantation and Advanced Specialized Therapies), via Tricomi 5, 90127 Palermo, Italy. gmamone@ismett.edu

Telephone: +39-91-2192292
Fax: +39-91-2192344

Received: June 20, 2016
Peer-review started: June 22, 2016
First decision: August 22, 2016
Revised: September 5, 2016
Accepted: September 28, 2016
Article in press: September 28, 2016
Published online: December 21, 2016

Abstract

Focal nodular hyperplasia (FNH) of the liver is a benign lesion occurring in 0.6%-3% of the general population that probably reflects a local hyperplastic response of hepatocytes to a vascular abnormality. Most lesions are diagnosed incidentally and the natural history of the disease remains largely unknown. It has been shown that most FNH remain stable, or even regress, over a long follow-up period. We present a patient with FNH of the liver who was followed up for 7 years. A 26-year-old woman with a 5-year history of oral contraceptive use was referred to our hospital in February 2005 for further examination of a liver tumour. The diagnosis of FNH was made using magnetic resonance (MR) imaging with hepatospecific contrast media; this technique allows a correct diagnosis, in particular distinguishing FNH from hepatic adenoma, avoiding an invasive procedure such as the lesion biopsy. After 7-year from the diagnosis, we observed the complete spontaneous regression of the lesion by enhanced MR scanning. In this patient, discontinuation of oral contraceptive use and two childbirths may have influenced the natural history of FNH. To our knowledge, in the English literature there is no report illustrating a complete regression of giant FNH but only studies of decreasing in size. The present case suggests that a young patient with giant FNH should be managed conservatively.
rather than by resection, because FNH has the potential for spontaneous regression.

**Key words:** Focal nodular hyperplasia; Regression; Magnetic resonance; Oral contraceptives; Pregnancy

© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: We present a patient with focal nodular hyperplasia (FNH) of the liver who was followed up for 7 years. A 26-year-old woman with a 5-year history of oral contraceptive use was referred to our hospital in February 2005 for further examination of a liver tumour. The diagnosis of FNH was made using magnetic resonance (MR) imaging with hepatospecific contrast media. After 7-year from the diagnosis, we observed the complete spontaneous regression of the lesion by enhanced MR scanning. In this patient, discontinuation of oral contraceptive use and two childbirths may have influenced the natural history of FNH.

Mamone G, Caruso S, Cortis K, Miraglia R. Complete spontaneous regression of giant focal nodular hyperplasia of the liver: Magnetic resonance imaging evaluation with hepatobiliary contrast media. *World J Gastroenterol* 2016; 22(47): 10461-10464 Available from: URL: http://www.wjgnet.com/1007-9327/full/v22/i47/10461.htm DOI: http://dx.doi.org/10.3748/wjg.v22.i47.10461

**INTRODUCTION**

Focal nodular hyperplasia (FNH) is a benign hepatic lesion common in young women; a localized increase in arterial blood flow produced by a vascular abnormality may be involved in the pathogenesis of FNH[1].

The natural history of FNH is still unknown, because long-term follow-up studies of histologically proven FNH have been performed only in small series of patients, with conflicting results[2-6].

Surgery or interventional radiology treatment are not recommended, except in few cases when the tumour compresses neighbouring organs, liver vessels or bile ducts[7].

We report a patient with giant FNH of the liver, in whom the complete spontaneous regression of the lesion was observed on enhanced magnetic resonance with hepatobiliary phase, after a 7-year period of observation.

**CASE REPORT**

A 26-year-old woman was referred to our centre in February 2005 with an incidentally detected liver lesion on an abdominal ultrasound done as part of the imaging work-up for mild abdominal pain. No relevant past medical or surgical history was elicited. The patient was on the oral contraceptive pill for the past five years. Physical examination and a routine biochemical liver screen were unremarkable.

Further imaging was performed by magnetic resonance imaging (MRI), using a hepatospecific contrast agent (Gd-BOPTA, MultiHance, Bracco Imaging, Milan, Italy). This showed a 11.5 cm T1 and T2 isointense mass lesion in the right liver lobe, with small central scar, mosaic arterial enhancement, iso to hypoenhancement to liver on the delayed venous phases, and uptake of Gd-BOPTA on the hepatobiliary phase at two hours post contrast administration (Figure 1A-C). These findings were considered pathognomonic for FNH, and a biopsy was therefore deemed unnecessary[8-10].

The patient discontinued the oral contraceptive pill soon after diagnosis. She had two successful gestations (in 2006 and 2010). A follow-up Gd-BOPTA enhanced MRI performed in January 2012 showed complete involution of the known FNH (Figure 1D-F), except for a subcentimetre hypointense area that was attributed to residual scarring. At present, the patient remains asymptomatic and is doing well.

**DISCUSSION**

FNH of the liver is a benign condition occurring in 0.6%-3% of the general population. Most lesions are diagnosed incidentally and the natural history of the disease remains largely unknown. It has been postulated that a localized increase in arterial blood flow produced by a pre-existing vascular abnormality may be involved in the pathogenesis of FNH, through an exaggerated hyperplastic response[11]. FNH is the second commonest benign lesion of the liver following hemangioma[12] and FNH nodules are well-circumscribed unencapsulated nodules composed of hyperplastic hepatocytes surrounded by fibrous bands radiating from a central fibrotic scar containing thick-walled arteries[1,11].

The natural history of FNH is still unknown, because long-term follow-up studies of histologically proven FNH have been performed only in small cohort of patients, with conflicting results[2-6]. Surgical or interventional radiological treatment is usually not advocated, except in the rare exceptional cases where large FNH compress neighbouring organs, liver vessels or bile ducts[7].

The non-invasive diagnosis of FNH was quite challenging prior to the introduction of MRI performed using hepatospecific contrast agents. The typical MR imaging features of FNH include the presence of a central scar, arterial enhancement, and sustained enhancement in the venous phases. FNH usually shows iso to slightly hypointensity on T1 and iso to slightly hyperintensity on T2 weighted images. FNH
nodules appear as bright, or brighter, than normal liver parenchyma on the hepatobiliary phase of MRI performed with such agents\(^{[8-10]}\), avoiding the need for imaging-guided biopsy.

The pathogenesis and natural history of FNH remain largely unknown\(^{[1-6]}\). A possible aetiological link to endogenous oestrogens has been considered given the female predominance and peak incidence during childbearing years\(^{[1]}\). Exogenous oestrogens might also promote growth and marked vascular changes in FNH, and are usually discontinued in patients with FNH\(^{[12-14]}\). Regression has been reported following withdrawal of the oral contraceptive pill\(^{[13-15]}\). To our knowledge, in the English literature there is no report illustrating a complete regression of giant FNH but only studies of decreasing in size. The available data is limited and conflicting, with some studies reporting that neither the size nor the number of FNH lesions were influenced by oral contraceptive use\(^{[3,4]}\) and that pregnancy was also not associated with FNH changes or complications\(^{[16]}\).

Therefore, the relationship between low-dose oestrogen, pregnancy and FNH remains controversial. In our patient, discontinuation of oral contraceptive use and two childbirths may have influenced the natural history of FNH. The present case suggests that asymptomatic FNH could be managed conservatively with discontinuation of the oral contraceptive pill, since this might promote spontaneous regression.

### COMMENTS

**Case characteristics**

The authors report a patient with giant focal nodular hyperplasia (FNH) of the liver, in whom the complete spontaneous regression of the lesion was observed on enhanced magnetic resonance with hepatobiliary phase, after a 7-year period of observation.

**Clinical diagnosis**

The patient remained asymptomatic and was doing well.

**Differential diagnosis**

No differential diagnosis.

**Laboratory diagnosis**

All labs were within normal limits.

**Imaging diagnosis**

A follow-up Gd-BOPTA enhanced magnetic resonance imaging (MRI) showed complete involution of the known FNH, except for a subcentimetre hypointense area that was attributed to residual scarring.

**Pathological diagnosis**

No pathological diagnosis.

**Treatment**

Discontinuation of the oral contraceptive pill.

**Related reports**

Regression of FNH has been reported following withdrawal of the oral contraceptive pill. To our knowledge, in the English literature there is no report
Mamone G et al. Complete spontaneous regression of FNH

illustrating a complete regression of giant FNH but only studies of decreasing in size. In our patient, discontinuation of oral contraceptive pill and two childbirths may have influenced the natural history of FNH.

**Term explanation**

FNH of the liver is a benign lesion occurring in 0.6%-3% of the general population that probably reflects a focal hyperplastic response of hepatocytes to a vascular abnormality.

**Experiences and lessons**

The present case suggests that asymptomatic FNH could be managed conservatively with discontinuation of the oral contraceptive pill, since this might promote spontaneous regression.

**Peer-review**

This manuscript is well-written and easy for readers to follow. It highlights the possibility that discontinuation of oral contraceptive pill and two childbirths may influence the lesion's regression. The hepatospecific contrast media used in MRI to clearly diagnose FNH is Gd-BOPTA. Overall, this paper can help improve readers' clinical practice.

**REFERENCES**

1. Wanless IR, Mawdsley C, Adams R. On the pathogenesis of focal nodular hyperplasia of the liver. *Hepatology* 1985; 5: 1194-1200 [PMID: 4065824 DOI: 10.1002/hep.1840050622]
2. Stocker JT, Ishak KG. Focal nodular hyperplasia of the liver: a study of 21 pediatric cases. *Cancer* 1981; 48: 336-345 [PMID: 7237404]
3. Di Stasi M, Caturelli E, De Sio I, Salmi A, Buscarini E, Buscarini L. Natural history of focal nodular hyperplasia of the liver: an ultrasound study. *J Clin Ultrasound* 1996; 24: 345-350 [PMID: 8873856]
4. Mathieu D, Kobreiter H, Maisen P, Rahmouni A, Cherqui D, Zafrani ES, Dhumeaux D. Oral contraceptive use and focal nodular hyperplasia of the liver. *Gastroenterology* 2000; 118: 560-564 [PMID: 10702207 DOI: 10.1016/S0016-5085(00)70262-9]
5. Leconte I, Van Beers BE, Lacrosse M, Sempoux C, Jamart J, Materne R, Baudrez V, Horsmans Y. Focal nodular hyperplasia: natural course observed with CT and MRI. *J Comput Assist Tomogr* 2000; 24: 61-66 [PMID: 10667661 DOI: 10.1097/00004728-200001000-00015]
6. Kuo YH, Wang JH, Lu SN, Hung CH, Wei YC, Hu TH, Chen CH, Yen YH, Lee CM, Eng HL. Natural course of hepatic focal nodular hyperplasia: a long-term follow-up study with sonography. *J Clin Ultrasound* 2009; 37: 132-137 [PMID: 18855931 DOI: 10.1002/jcu.20533]
7. Amsur N, Hammond JS, Zakjo AB, Geller DA, Gamblin TC. Management of unctrollable symptomatic focal nodular hyperplasia with arterial embolization. *J Vasc Interv Radiol* 2009; 20: 543-547 [PMID: 19328431 DOI: 10.1016/j.jvir.2009.01.001]
8. Grazioi L, Morana G, Kirchin MA, Schneider G. Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study. *Radiology* 2005; 236: 166-177 [PMID: 15955857 DOI: 10.1148/radiol.221301039]
9. Grazioi L, Morana G, Federle MP, Brancatelli G, Testoni M, Kirchin MA, Menlli K, Olivetti L, Nicoli N, Procacci C. Focal nodular hyperplasia: morphologic and functional information from MR imaging with gadobenate dimeglumine. *Radiology* 2001; 221: 751-739 [PMID: 11791669 DOI: 10.1148/radiol.221301039]
10. Pirovano G, Vanuzzi A, Marti-Bonnati L, Grazioi L, Manfredi R, Greco A, Holzknecht N, Daldrup-Link HE, Rummeny E, Hamm B, Arnesen V, Imperatori L, Kirchin MA, Spinazzi A. Evaluation of the accuracy of gadobenate dimeglumine-enhanced MR imaging in the detection and characterization of focal liver lesions. *AJR Am J Roentgenol* 2000; 175: 1111-1120 [PMID: 1100175 DOI: 10.2214/ajr.175.4.1751111]
11. Nguyen BN, Flejou JF, Terris B, Belghiti J, Degott C. Focal nodular hyperplasia of the liver: a comprehensive pathologic study of 305 lesions and recognition of new histologic forms. *Am J Surg Pathol* 1999; 23: 1441-1454 [PMID: 10584697 DOI: 10.1097/0000478-199912000-00001]
12. Pain JA, Gimson AE, Williams R, Howard ER. Focal nodular hyperplasia of the liver: results of treatment and options in management. *Gut* 1991; 32: 524-527 [PMID: 2040476 DOI: 10.1136/gut.32.5.524]
13. Aldinger K, Ben-Menachem Y, Whalen G. Focal nodular hyperplasia of the liver associated with high-dosage estrogens. *Arch Intern Med* 1977; 137: 357-359 [PMID: 190958 DOI: 10.1001/archinte.1977.03630150057016]
14. Scott LD, Katz AR, Duke H, Cowan DF, Makld NF. Oral contraceptives, pregnancy, and focal nodular hyperplasia of the liver. *JAMA* 1984; 251: 1461-1463 [PMID: 6700042 DOI: 10.1001/jama.1984.03340350051028]
15. Ross D, Pina J, Mirza M, Galvan A, Ponce L. Letter: Regression of focal nodular hyperplasia after discontinuation of oral contraceptives. *Ann Intern Med* 1976; 85: 203-204 [PMID: 942141 DOI: 10.7326/0003-4819-85-2-203]
16. Weimann A, Mösinger M, Frohnhoff K, Nadalin S, Raab R. Pregnancy in women with observed focal nodular hyperplasia of the liver. *Lancet* 1998; 351: 1251-1252 [PMID: 9643751 DOI: 10.1016/S0140-6736(05)70318-1]

**P- Reviewer:** Liu GJ  **S- Editor:** Yu J  **L- Editor:** A  **E- Editor:** Zhang FF
